Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Turmetabart Adizutecan · ABBV-706

Antibody-drug conjugate · Cytotoxic, directed at SEZ6 · developed by AbbVie

Phase 3 Most advanced trial
ABBV Developer
1 Registered trials

What is Turmetabart Adizutecan?

Turmetabart adizutecan is an antibody-drug conjugate combining turmetabart, a monoclonal antibody targeting SEZ6, with adizutecan, a topoisomerase 1 inhibitor. The antibody binds SEZ6 on tumor cells, allowing internalization and release of the cytotoxic payload to inhibit DNA replication. It is studied in small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ABBV-706
Drug type
Antibody-drug conjugate
Targets
SEZ6, topoisomerase 1 (TOP1) (secondary target)
Mechanism
Cytotoxic, directed at SEZ6
Pathways
DNA replication inhibition, apoptosis
Therapy area
Oncology
Developer
AbbVie (ABBV)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
U9G63L4FA6

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07365241 Phase 3 Small Cell Lung Cancer Recruiting ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Small Cell Lung Cancer

More from AbbVie

Adalimumab FDA approved Atogepant FDA approved Pivekimab Sunirine FDA approved Risankizumab FDA approved Telisotuzumab Vedotin FDA approved Upadacitinib FDA approved Venetoclax FDA approved ABBV-1042 Phase 1 ABBV-291 Phase 1 ABBV-295 Phase 2 ABBV-313 Phase 1 ABBV-324 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind Turmetabart Adizutecan

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.